Histopathological and Cytological Biomarkers for Breast and Gynecologic Cancers
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (20 May 2025) | Viewed by 1294
Special Issue Editors
Interests: cytopathology; immunohistochemistry; cancer; systematic review and meta-analysis; medical education
Special Issues, Collections and Topics in MDPI journals
Interests: pathology; cancer pathology; colorectal cancer; lung cancer; pancreatic cancer; breast cancer; inflammation; infectious agents; cell cycle; metabolism
Special Issues, Collections and Topics in MDPI journals
Interests: pathology; hematopathology; cytology; metaanalysis; digital pathology; artificial intelligence
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Breast and gynecologic malignancies are major causes of morbidity and mortality worldwide. To diagnose them, histopathological or cytopathological sampling is performed, and selected biomarkers related to diagnosis, prognosis, and therapy are routinely evaluated. There has been tremendous progress in the fields of breast and gynecological cancers, which is highlighted by the presence of well-defined molecular subtypes and tailored therapies. However, discovering new biomarkers would enhance the management of these patients. This Special Issue welcomes original studies, reviews, and short communications, aiming to address novel biomarkers assessed in tissue or cytological material of patients with breast or gynecologic malignancies. Large-scale studies evaluating well-established rather than candidate biomarkers or presenting negative findings are also welcome. Potential topics include the following:
- Biomarkers tested on cytological (e.g., fine needle aspirations, malignant effusions, cervical cytology) or histopathological material;
- Biomarkers related to diagnosis, prognosis, or therapy of patients with breast or gynecologic cancers;
- Biomarkers assessed with immunohistochemistry or immunocytochemistry;
- Biomarkers assessed with high-throughput molecular techniques (e.g., next-generation sequencing or mass spectrometry);
- Biomarkers predicting response to immunotherapy;
- Biomarkers measured with the aid of digital pathology and artificial intelligence;
- Biomarker testing highlighting cytopathological correlation;
- Systematic reviews and meta-analyses focusing on well-established biomarkers tested on tissue biopsy or cytology specimens.
Dr. Ilias P. Nikas
Dr. Ioannis Pateras
Prof. Dr. Yosep Chong
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pathology
- cytopathology
- malignant effusions
- biomarker
- breast cancer
- ovarian cancer
- endometrial cancer
- cervical cancer
- metastasis
- immunohistochemistry
- immunocytochemistry
- immunotherapy
- genomics
- proteomics
- personalized medicine
- prognosis and therapy
- digital pathology
- artificial intelligence
- machine learning
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
